CJ PARTNERS
CJ PARTNERS
Logo6.png
 
 

A Life Science Consultancy in
Tokyo, Japan

 
 
 
 
 
 
 
tokyo_bg3.jpg
 

Uji yori sodachi

CJ PARTNERS (CJP) fulfills a need for true cross-cultural and bilingual strategic and regulatory support between Japan and the West. We were founded on the concept of uji yori sodachi: nurture over nature. Born to western families but culturally and professionally raised in Japan, CJP's founders’ true bi-cultural origins provide us with a unique advantage and has enabled us to link businesses in the West and Japan in a manner no other firm can.

With the advent of the new Japanese regenerative medicine laws in 2014, CJP positioned itself to cater to the unique requirements of non-Japanese biotechs looking to complete clinical development and commercialize in Japan. Throughout the years CJP has developed close relationships with senior management across Japanese pharma and venture capital. We have also worked closely with the PMDA (the Japanese equivalent of the FDA/EMA) while conducting a significant portion of all official consultations. CJ PARTNERS has become the go-to professional service not only for biotechs looking to enter the Japanese market but also for Japanese pharma looking to find the most advanced therapies in development around the globe. Our bi-cultural and bilingual origins enable us to effectively communicate with and instill confidence in parties on both sides of the table.

In addition to our life science work, CJP has taken on a variety of projects assisting companies with their Japan strategy in markets such as FinTech and retail among others.

 
 

Life Science Consulting & Advisory

Entering the Japanese market can be daunting. CJ PARTNERS provides extensive market analysis to pave your way forward in Japan. We further leverage our close relationships with domestic industry players and academic institutions to find you the right partners from clinical research to commercialization.

The PMDA (Japanese equivalent to the FDA/EMA) has led the regulatory charge into the regenerative medicine space, but much of the knowledge regarding the regulations is locked behind linguistic doors. CJP provides clients with proprietary translations and interpretations of these guidelines. CJP has conducted a significant number of official consultations for multiple clients with the PMDA across a variety of indications and technologies, making CJP the go-to advisor in the field.

CJP also supports its clients' financial endeavors from capital raising, which CJP has successfully executed for many of its clients, to exits, such as an IPO. It is often unknown outside of Japan that the Tokyo Stock Exchange's Mothers market has a track record of high-valued biotech IPOs. The Japan Depository Receipt (JDR) provides foreign companies an easy conduit into the TSE, and CJP has the experience and relationships required to prepare for and execute an IPO in Japan.

CJP offers its services across four pillars.

 

Market Analysis

Market Size, Growth, and Competitor Analysis

Key Player and KOL Identification

Market Entry and Regulatory Pathway Strategy…

Strategic Partners

Partner Identification and Negotiation

Local Manufacturing and Distribution

Contract Execution...

Clinical Operations

Site Selection

Protocol Design

Clinical Trial Monitoring…

 

Regulatory Advisory

Japanese Guideline Interpretation

Quality & Safety and Protocol Documentation Preparation

PMDA Consultation Representation and Advisory…

Financial Strategy

Capital Raising

Local JV/Subsidiary Establishment

Japan IPO Strategy Development and Execution…

 
cjp_dark_blue.png
 
 

CJ PARTNERS prides itself on its deep knowledge of the Japanese regenerative medicine industry and regulations. We additionally maintain several detailed databases of cell and gene therapies under development worldwide.

 
 

Annual PMDA Consultations

Regenerative Medicine in Japan

First presented at Cell & Gene Therapy World in Washington DC in 2016, this regularly updated deck provides an overview of Japan's regulatory environment as well as the processes necessary to commercialize products in Japan, from Official Consultations with the PMDA to pricing methods used by the Central Social Insurance Medical Council Reimbursement. Additionally, it provides a brief look at the regenerative medicine market in Japan, including the major players in research, manufacturing, and commercialization.

Contact us for additional insight.

 

Cellular Therapies by Region

Proprietary Databases

CJ PARTNERS maintains databases for cell and gene therapies developed worldwide. We provide more than your standard database and dig deep for public data including indication area, cell type and source, current phase of development, and technologies used (e.g. ex/in vivo, autologous/allogeneic, vectors, etc.). To date, our databases include information for over 1,700 cell and gene therapy products being developed by over 400 different companies.

 
 
cjp_logo_empty_whiteborder2.png
 

Media

CJ PARTNERS is frequently called upon to provide expert opinions on the state of regenerative medicine in Japan. We have made appearances in journals such as the Harvard Business Review and StreetWise Reports as well as presented at industry meetings such as Cell & Gene Therapy World and ISCT.

Contact us for interview and speaking requests.

 

Our Office

Hiroo Nishikawa Bldg. 3F
Hiroo 5-22-3, Shibuya-ku, Tokyo
150-0012 Japan

 
 
cjp_dark_blue.png